PRIMARY OBJECTIVES:
1.1 Determine the current practice patterns use of colony stimulating growth factors during chemotherapy in the UT MD Anderson Cancer Center (UTMDACC) Gynecology Oncology Center.
1.2 Establish if evidence-based educational interventions supported by a practice guideline influences a change in clinical practice in the UT MD Anderson Cancer Center (UTMDACC) Gynecology Oncology Center.
A change in clinical practice will be demonstrated by an increase in the percent of patients treated by standards set in the NCCN Myeloid Growth Factor Guideline, including the appropriate setting (primary or secondary prophylaxis), use level (including appropriate use at febrile neutropenia (FN) risk levels above 20% and inappropriate use at FN risk levels below 10%), and dosing based on regimen and patient risk factors.
SECONDARY OBJECTIVES:
1.3 Compare and contrast the incidence of treatment delays and patient satisfaction with chemotherapy experience before and after the evidence-based educational interventions..
1.4 Compare and contrast the incidence of chemotherapy-induced neutropenia (CIN); chemotherapy-induced febrile neutropenia (FN) and FN related hospitalizations (FNH) along with the frequency of these complications by cycle with chemotherapy regimens commonly used for the treatment of gynecologic malignancies before and after the evidence-based educational interventions.
1.5 Compare and contrast the hospitalization and anti-infective utilization rates associated with CIN, FN, FNH before and after the evidence-based educational interventions.
1.6 Identify the patient demographic characteristics and risk factors associated with CIN, FN, FNH. |